These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32263505)

  • 1. How can nanomedicines overcome cellular-based anticancer drug resistance?
    Sobot D; Mura S; Couvreur P
    J Mater Chem B; 2016 Aug; 4(30):5078-5100. PubMed ID: 32263505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming cellular multidrug resistance using classical nanomedicine formulations.
    Kunjachan S; Błauż A; Möckel D; Theek B; Kiessling F; Etrych T; Ulbrich K; van Bloois L; Storm G; Bartosz G; Rychlik B; Lammers T
    Eur J Pharm Sci; 2012 Mar; 45(4):421-8. PubMed ID: 21907796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.
    Zhou L; Wang H; Li Y
    Theranostics; 2018; 8(4):1059-1074. PubMed ID: 29463999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
    Mao C; Li F; Zhao Y; Debinski W; Ming X
    Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming multidrug resistance with nanomedicines.
    Ganoth A; Merimi KC; Peer D
    Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.
    Pillai G; Ceballos-Coronel ML
    SAGE Open Med; 2013; 1():2050312113513759. PubMed ID: 26770691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
    Tekchandani P; Kurmi BD; Paliwal SR
    Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.
    Ahmad J; Akhter S; Greig NH; Kamal MA; Midoux P; Pichon C
    Curr Pharm Des; 2016; 22(28):4360-4373. PubMed ID: 27319945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines for Overcoming Cancer Drug Resistance.
    Hu T; Gong H; Xu J; Huang Y; Wu F; He Z
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
    Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
    Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells.
    Shi Q; Zhang L; Liu M; Zhang X; Zhang X; Xu X; Chen S; Li X; Zhang J
    Biomaterials; 2015 Oct; 67():169-82. PubMed ID: 26218743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
    Lakshmanan VK
    Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential of Zebrafish as a Model Organism for Improving the Translation of Genetic Anticancer Nanomedicines.
    Gutiérrez-Lovera C; Vázquez-Ríos AJ; Guerra-Varela J; Sánchez L; de la Fuente M
    Genes (Basel); 2017 Nov; 8(12):. PubMed ID: 29182542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.